3-boc-3,7-二氮杂双环[4.2.0]辛烷 | 885271-67-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3-boc-3,7-二氮杂双环[4.2.0]辛烷
• 英文名称: Tert-butyl 3,7-diazabicyclo[4.2.0]octane-3-carboxylate
• CAS: 885271-67-0；1250993-51-1
• 化学式: C₁₁H₂₀N₂O₂
• mdl: MFCD08234914
• 分子量: 212.29
• InChiKey: TUIAJQPTVCSWOB-UHFFFAOYSA-N

物化性质

• 沸点：
  295.4±40.0 °C(Predicted)
• 密度：
  1.076±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.909
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] PYRAZOLOPYRIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE<br/>[FR] COMPOSÉS AMINE PYRAZOLOPYRIDINIQUES POUR LE TRAITEMENT D'UNE MALADIE AUTO-IMMUNE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2020052738A1

  公开（公告）日：2020-03-19

  The present invention relates to compounds of formula (I), wherein R1, R2, R3,R4 and X are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

  本发明涉及式(I)的化合物，其中R1，R2，R3，R4和X如此描述，以及它们的药学上可接受的盐、对映体或二对映体，以及包括这些化合物的组合物和使用这些化合物的方法。
• Fused bicyclic inhibitors of menin-MLL interaction
  申请人：Janssen Pharmaceutica NV

  公开号：US10975100B2

  公开（公告）日：2021-04-13

  The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

  本发明涉及可用于哺乳动物治疗和/或预防的药物制剂，尤其涉及融合双环化合物、包含此类化合物的药物组合物，以及它们作为门宁/MLL 蛋白/蛋白相互作用抑制剂的用途，可用于治疗癌症、骨髓增生异常综合征（MDS）和糖尿病等疾病。
• PYRAZOLOPYRIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3849974A1

  公开（公告）日：2021-07-21
• FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION
  申请人：Janssen Pharmaceutica NV

  公开号：US20200172556A1

  公开（公告）日：2020-06-04

  The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
• NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
  申请人：Hoffmann-La Roche Inc.

  公开号：US20210300947A1

  公开（公告）日：2021-09-30

  The present invention relates to compounds of formula (I), ab (I), wherein R1 to R3 and L are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.